Sohanya Cheng - Aug 31, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP & Chief Commercial Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng
Stock symbol
KPTI
Transactions as of
Aug 31, 2022
Transactions value $
$0
Form type
4
Date filed
9/1/2022, 09:00 PM
Previous filing
Jun 14, 2022
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +30K +33.35% $0.00 120K Aug 31, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPTI Stock Option (right to buy) Award $0 +45K $0.00 45K Aug 31, 2022 Common Stock 45K $5.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.
F2 This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024.